M&T Bank Free cash flow increased by 96.1% to $916.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 50.2%, from $610.00M to $916.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 2.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $523.53M | $443.61M | $635.13M | $1.27B | $1.13B | $1.10B | $866.69M | $373.00M | $1.21B | $1.35B | $712.00M | $573.00M | $1.29B | -$58.00M | $1.59B | $610.00M | $818.00M | $965.00M | $467.00M | $916.00M |
| QoQ Change | — | -15.3% | +43.2% | +99.6% | -11.1% | -2.6% | -21.1% | -57.0% | +224.7% | +11.7% | -47.4% | -19.5% | +124.8% | -104.5% | >999% | -61.7% | +34.1% | +18.0% | -51.6% | +96.1% |
| YoY Change | — | — | — | — | +115.4% | +147.5% | +36.5% | -70.6% | +7.4% | +23.2% | -17.8% | +53.6% | +6.4% | -104.3% | +123.5% | +6.5% | -36.5% | >999% | -70.6% | +50.2% |